Literature DB >> 2943405

Chronic paroxysmal hemicrania. X. On the autonomic involvement.

O Sjaastad, J Aasly, T Fredriksen, M M Wysocka Bakowska.   

Abstract

In four patients with chronic paroxysmal hemicrania, two of whom could precipitate attacks mechanically, various autonomic function tests were carried out in connection with attacks. Not all features could be studied in all patients. Forehead sweating and temperature were measured. Sweating, tearing, and nasal secretion were studied after systemic atropine administration, which reduced attack-related sweating, tearing, and nasal secretion markedly. Intra-ocular pressure was measured before and after the topical administration of an alpha-receptor blocking agent, thymoxamine. After topical thymoxamine no definite intra-ocular pressure increase occurred during precipitated attacks. In attacks precipitated by head movements, forehead sweating occurred seconds (up to 30 sec) before the pain. This study indicates that at least in some CPH cases, forehead sweating is not caused by the pain. Nor is the pain secondary to increase in intra-ocular pressure. The thymoxamine experiments seem to indicate that alpha-receptors in some way may be connected with the intra-ocular pressure increase during attack.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2943405     DOI: 10.1046/j.1468-2982.1986.0602113.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  3 in total

Review 1.  Effective management of ice pick pains, SUNCT, and episodic and chronic paroxysmal hemicrania.

Authors:  L C Newman
Journal:  Curr Pain Headache Rep       Date:  2001-06

Review 2.  SUNCT Syndrome: diagnosis and treatment.

Authors:  Juan A Pareja; Ana B Caminero; Ottar Sjaastad
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 3.  Pupillary abnormalities due to sympathetic dysfunction in different forms of idiopathic headache.

Authors:  M De Marinis
Journal:  Clin Auton Res       Date:  1994-12       Impact factor: 4.435

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.